Pluri Inc
Company Profile
Business description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Contact
MATAM Advanced Technology Park
Building No. 5
Haifa3508409
ISRT: +972 747108600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
142
Stocks News & Analysis
stocks
Strong guidance from undervalued ASX share
stocks
TSMC earnings: Refining guidance and expansion plans amid strong AI demand
stocks
Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,155.90 | 20.20 | 0.22% |
| CAC 40 | 8,262.70 | 11.87 | -0.14% |
| DAX 40 | 24,154.47 | 87.77 | 0.36% |
| Dow JONES (US) | 48,578.72 | 115.00 | 0.24% |
| FTSE 100 | 10,589.99 | 30.41 | 0.29% |
| HKSE | 26,046.70 | 347.56 | -1.32% |
| NASDAQ | 24,102.70 | 86.69 | 0.36% |
| Nikkei 225 | 58,994.41 | 523.93 | -0.88% |
| NZX 50 Index | 12,962.32 | 103.74 | -0.79% |
| S&P 500 | 7,041.28 | 18.33 | 0.26% |
| S&P/ASX 200 | 8,935.90 | 25.80 | 0.29% |
| SSE Composite Index | 4,043.45 | 12.10 | -0.30% |